Table 3.

Clinical trials of STACs and NAD+ boosters in cardiovascular and metabolic diseases

Drug	Effect	Study Population	Reference
Resveratrol	No change in walking performance	Patients with peripheral artery disease	213
	↑ Vascular function No change in glucose metabolism	Glucose intolerant adults	214
	↓ systolic blood pressure ↑ Insulin sensitivity	Healthy obese men	207
	No effect	Healthy non-obese men	208
	↓ Body weight ↓ Fat mass ↓ Total insulin secretion	Metabolic syndrome patients	209
	↓ Insulin resistance ↓ Fasting glucose	Type 2 diabetes patients	210
	↑ Endothelial function ↑ Diastolic function	Patients with coronary artery disease	211
	↓ Serum LDL ↓ Insulin resistance	NAFLD patients	224
	↓ Hepatic steatosis ↓ Inflammation	NAFLD patients	212
SRT2104	↓ Body weight Changes to glucose control	Type 2 diabetes patients	217
	↓ Serum LDL ↓ Serum TGs	Healthy older volunteers	215
	↓ Serum LDL ↓ Serum TGs	Healthy smokers	216
Niacin	↓ Dyslipidemia	Varied	202
NRPT	Safely tolerated	Healthy volunteers	221
NR	Safely tolerated	Healthy volunteers	218,219
	↓ blood pressure ↓ arterial stiffening	Healthy volunteers	220
	Underway, aim to improve astherosclerosis and heart failure	Varied	#NCT02812238 #NCT03423342 (Clinicaltrials.gov)
NMN	Underway, aim to improve cardiometabolic outcomes	Women 55+ with dyslipidemia	#NCT03151239 (Clinicaltrials.gov)
INO-1001	Safely tolerated	Patients with myocardial infarction	223